The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,629.00
Bid: 1,629.00
Ask: 1,629.50
Change: -11.00 (-0.67%)
Spread: 0.50 (0.031%)
Open: 1,633.00
High: 1,641.00
Low: 1,611.00
Prev. Close: 1,640.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chief executives and the itch to quit

Thu, 16th May 2013 07:04

By Andrew Callus

LONDON, May 16 (Reuters) - On approaching his 60th birthdaythis year, long-serving Tullow Oil boss Aidan Heaveytold staff he felt "like two 30 year-olds".

A handful of recent shock departures by 50-something chiefexecutives at European blue chip companies - none of them underany obvious pressure to quit - suggest some of his peers eitherlack that vigour, or want to channel it elsewhere.

Peter Voser is giving up one of the world's most challengingCEO roles at Royal Dutch/Shell next year, before his55th birthday, in pursuit of a "lifestyle change".

Swiss engineering group ABB's 55-year old boss Joe Hogan is also going, for "private reasons". Pierre-OlivierBeckers, 53, is walking out on Belgian retailer Delhaize, and Paul Walsh, 57, is waving goodbye to drinksmultinational Diageo.

All four are about average European CEO age.

While the rising financial rewards of running a modernmultinational have been well publicised, executive recruiterssay the pressures of the job have also been ratcheted up inrecent years, and not just because of the tough economic times.

"The reality is it's gruelling. It's really tough, and therecomes a point where you don't want to do it any more," said IanButcher, who headhunts board-level and senior executives for MWMConsulting.

"The quarterly reporting, the governance, the regulatoryaspects, it just becomes very wearing - the level of scrutiny,the pace at which things are moving, the short-term nature ofhow people look at any given situation. Even over the past fiveyears these things have made CEO a tougher position to hold, andthe travel that people have to undertake in these jobs - it'sjust something they run out of steam on."

Some recent early retirees, while still well short oftraditional retirement age, also got to the top spot early.

"They're still in their early fifties, with energy and adesire to do something, but they want to do something different,something quite significantly different sometimes," saysButcher.

Voser fits that bill. He has no plans to collect well-paidchairmanships and non-executive directorships, as many ex-CEOshave done in the past. Former Tesco chief Terry Leahyhas also resisted that gravy train since he left two years ago.

As for the early starters, executive search industryprofessionals point at people like Andrew Witty, the CEO ofGlaxoSmithKline, who took on the job aged 44 in 2008 andwould have to stay in harness for another decade to reach 60 inthe role.

Blue-chip bosses as young as Witty are still rare, but overa quarter of Europe's current crop have less than two years inthe job, and more than half have less than four, according todata from executive search specialists BoardEx.

MEDIAN CEO AGE IS 55 YEARS

The BoardEx data, collected for Reuters from 238 companiesin the main stock indexes of Germany, Britain, France, Spain,Italy, Belgium, the Netherlands and Denmark, puts the median CEOage at 55, and the median tenure at four years. Only 16 percentof the group have held on for 10 years and more.

The longest serving of them is Martin Gilbert of the Britishfund Aberdeen Asset Management. Though younger, at 57,Gilbert pips the 28.3-year tenure of Tullow's double thirtyyear-old Heavey, with 29.8 years at the helm.

There are 17 top European CEOs who have been in the job forless than six months, and the youngest of the 225 in the groupfor whom ages were available is Vitaly Nesis, 37, who runsPolymetal International, the London-listed Russianprecious metals miner.

While the recent spate of quitters are looking for somethingelse to do, there are still some who appear to want nothing but.

In the BoardEx group there are four over 70, and the oldestby eight years is Albert Frere, CEO of Group Bruxelles Lambert.

Perhaps some linger on for fear that the pension pot isstill a little light. Frere will have put such qualms behind himlong ago. At 87, he is Belgium's richest man.

More News
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more
1 Sep 2023 07:49

LONDON BRIEFING: Stocks seen higher; UK house prices continue to fall

(Alliance News) - Stocks in London are set to open higher on Friday as markets looked ahead to a data-heavy day.

Read more
1 Sep 2023 07:12

Japan considering GSK's Nucala drug for sinusitis treatment

(Sharecast News) - Japanese regulators are reviewing a new drug application for GSK's Nucala treatment to be used for the treatment of form of adult sinusitis, the biopharma giant announced on Friday.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more
23 Aug 2023 08:17

GSK gets positive results from shingles trial of Shingrix in China

(Alliance News) - GSK PLC on Wednesday celebrated positive results from the first-ever efficacy trial of its preventative shingles treatment, Shingrix, in China.

Read more
23 Aug 2023 07:04

GSK reports positive results from shingles vaccine trials in China

(Sharecast News) - GSK reported significant positive findings from its first efficacy trial of the 'Shingrix' shingles vaccine in China on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.